Recent

% | $
Quotes you view appear here for quick access.

Immunomedics Inc. Message Board

  • headsupeyesclosed headsupeyesclosed Jan 27, 2013 11:40 PM Flag

    Two huge patents granted in last few months signal major upcoming partnership IMO

    ---------------------------------------------------------------------------------------------------------------------------------------------

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • MORRIS PLAINS, N.J., Dec. 21, 2012 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that it has received notice that its patent application for "Anti-CD19 antibodies," will issue as US patent No. 8,337,840 on December 25, 2012.
      The allowed claims under the patent cover the use of specific humanized anti-CD19 monoclonal antibodies and fragments thereof for the treatment of autoimmune diseases. The antibodies and fragments thereof can be used alone, conjugated to at least one therapeutic agent or in combination with other humanized, chimeric, human or murine monoclonal antibodies, such as antibodies reactive with CD20, CD22, CD74 or HLA-DR.
      This patent, which provides coverage until 2024, also protects (19)-3s, a novel T-cell redirecting agent made as a DOCK-AND-LOCK(TM) (DNL(TM)) complex using the Company's patented platform technology. The DNL(TM) complex recognizes CD19 on B cells and binds to CD3 on T cells. At the 2012 Annual Meeting of the American Society of Hematology, (19)-3s was reported to bind to T cells and non-Hodgkin lymphoma (NHL) cells simultaneously, and induce T-cell-mediated killing of NHL cells at less than 1 picomolar (pM) concentrations in an ex vivo setting, with maximal activity at 10 pM.

      • 1 Reply to headsupeyesclosed
      • MORRIS PLAINS, N.J., Jan. 8, 2013 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, announced that IBC Pharmaceuticals, Inc. (IBC), a majority-owned subsidiary, has received notice that its patent application for "Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases," will issue as U.S. patent no. 8,349,332 today.
        This patent, which provides coverage until 2026, concerns methods of use of hexavalent DOCK-AND-LOCK(TM) (DNL(TM)) constructs, comprising antibodies and/or antigen-binding antibody fragments tethered together using the Company's patented platform technology. The allowed claims cover bispecific antibodies that bind to CD20 and CD22 antigens on B cells. The DNL(TM) complexes are of use for the treatment of B-cell malignancies or B-cell-related autoimmune diseases.
        At the 2012 Annual Meeting of the American Society of Hematology, the Company reported potent anti-tumor activity of a new class of hexavalent bispecific antibodies targeting CD20 and CD22 in an animal model of human non-Hodgkin lymphoma. These DNL(TM) complexes extended the median survival time of animals in a statistically significant manner.

 
IMMU
4.465-0.075(-1.65%)12:54 PMEDT